Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, Elisa Kits, Enzymes, Reagents, RNA
Development of A Predictive Model for Work-Relatedness of MSDs Among Semiconductor Back-End Workers
Objective: There are limited models available to predict the linkages of musculoskeletal work (MSDS) among semiconductor back-end workers. This study seeks to overcome the gap through the development of predictive models for this specific population. Methods: Potential MSDS Risk Factors Extracted from 277 Ergonomic Investigation Reports for Work Compensation Claims conducted between 2011 – 2019.
Binary logistic regression approach is used to determine the predictor of extracted data. Result: significant predictor (p <0.05) includes poor posture (or = 1.822; 95% CI [1,261,2,632]), strong activity (or = 1.741; 95% CI [1,281,2,367)), static posture ( or = 1,796); 95% CI [1,367,2,378]), the appointment (or = 1.438; 95% CI [0.966,1,880]), transferred (or = 1.533; 95% CI [1,101,136]), push-pull (or = 0.990; 95% CI [0.744,1,317])), fix (or = 0.845; 95% CI [0.616,1,159]), preventive maintenance (or = 1,061; 95% CI [0.765,1,471]) and quality inspection (or = 0.982; 95% CI [0.729,1,322]).
Personal factors and labor duration also play an important role in this prediction model. The accuracy of the model carried out through cross validation with 30 new data sets is 86.2%. Face validation activities among 30 experts show promising results, with a score of the average agreement on predictor inclusion which will be assessed at 7.9 / 10 (SD = 1.9). Conclusion: This model allows practitioners to predict the potential of MSD cases among semiconductor back-end workers, and proactively plan the right mitigation measures.
Data collection in multiple sclerosis: MSDS Approach
Multiple Sclerosis (MS) is a chronic inflammatory disease that often occurs in the central nervous system that affects patients for decades. As MS monitoring and treatment becomes more personalized and complex, assessment and collection of different parameters ranging from clinical assessment through laboratories and imaging data to data reported by patients becomes increasingly important for innovative patient management in MS. These aspects are predestin electronic data processing for use in MS documentation.
Such technology allows fast health information exchange between patients, practitioners, and caregivers, regardless of time and location. In this paper perspective, we present our digital strategy from Dresden, where we are developing multiple sclerosis Documentation System (MSDS) into the EHEALTH platform that can be used for various purposes. Various use cases are presented that apply this software platform and offer an important perspective for the management of innovative digital patients in the future. MS holistic patient management, electronically supported by clinical lines, will have an important impact on other patient care fields, such as neurorehabilitation.
RAMP package for MSD risk management in handling manuals – tools that can be accessed freely, with website and training courses.
In this paper, the ramp package is served with the aim of facilitating the application of ramp tools to systematically manage MSD risk. This package consists of ramp tools (risk assessment and management tool for proactively handling manuals), websites ramp, and free, globally available, training courses (MOOCs). The module of action used to manage the identified MSD risk is introduced. This tool, which includes various risks, applies to the entire risk management process.
Next, the ramp is open openly for download, and free to use. Ramp tools and training materials are developed using participatory iterative methodologies including researchers and practitioners. Ramp is downloaded in 86 countries in the first 26 months since it was launched and more than 2400 students from high and low income countries have joined the MOOC. RAMP packages meet the needs of organizations for risk assessment tools and comprehensive risk management.
The prevalence of MSDS and risk assessment of posture on the floor mopping activities through subjective and objective steps.
Housing and commercial cleaning is part of our daily routine to maintain sanitation around the environment. Professional health care involved in such cleaning activities has been a major concern throughout the world. This study investigated the risk of musculoskeletal disorders in professional cleaners involved in mopping floor assignments. Cross-sectional studies were carried out on 132 professional mopping using the modified Nordic questionnaire. Pearson correlation tests are implemented to study the relationship of pain felt by work experience. Muscle strains and postural risks are evaluated using three-channel electromyography and real-time movement taking each of 15 professionals during the mopping floor.

Regarding musculoskeletal injury, the risk reported in the majority in the right hand, lower back, left wrist, right shoulder, left biceps, and worker’s right wrist. Work experience has a low negative relationship with MSDS on the left wrist, right wrist, right elbow, lower back, and right arm (P <0.01). The EMG surface shows the occurrence of higher muscle activity in the muscle of trapezius and biceps brisachi (BB) over and the muscles of flexor carpi are dominant and the BB muscles from the hands that are not dominant at the top and bottom of the mop stem, respectively.
The relationship between the body mass index and pain intensity among veterans with musculoskeletal disorders: findings from the MSD cohort study.
To check the relationship between the body mass index (BMI) and the intensity of pain among veterans with the diagnosis of musculoskeletal disorders (MSDS; nontraumatic joints; osteoarthritis; lower back pain, back, and neck). Veteran Health Record Data (VHA). The national cohort of US military veterans with MSDS in VHA CARE during 2001-2012 (n = 1,759,338). These cross-sectional data were analyzed using the negative binomial model of pain intensity as a BMI function, adjusted to comorbidity. and demographics.
Samples have an average age of 59.4, 95% are men, 77% white / non-Hispanic, 79% overweight or obese, and 42% report no pain in the diagnosis of the MSD index. Overall, there is a J-shaped relationship between BMI and pain (Nadir = 27 kg / m2), with severe obesity (BMI ≥ 40 kg / m2) most likely to report pain (or vs. normal weight = 1.23, 95% interval trust = 1.21-1.26).
Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
43R-ID047AF |
Fitzgerald |
500 ug |
EUR 462 |
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
Donkey anti Chicken IgY (H + L) (Alexa Fluor 594) |
43R-ID056AF |
Fitzgerald |
500 ug |
EUR 343 |
Description: Donkey anti Chicken IgY secondary antibody (H + L) (Alexa Fluor 594) |
Rabbit anti Chicken IgY (H + L) (Alexa Fluor 594) |
43R-IR016AF |
Fitzgerald |
1 mg |
EUR 281 |
Description: Rabbit anti Chicken IgY (H + L) secondary antibody (Alexa Fluor 594) |
Endoglin/CD105 Alexa Fluor |
FC15024 |
Neuromics |
100 Tests |
EUR 448 |
Goat Anti-Mouse IgG(H+L) Alexa Fluor 594–conjugated |
S0005 |
Affbiotech |
200ul |
EUR 376 |
Goat Anti-Rabbit IgG(H+L) Alexa Fluor 594–conjugated |
S0006 |
Affbiotech |
200ul |
EUR 376 |
Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
43R-ID012AF |
Fitzgerald |
300 ug |
EUR 410 |
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated |
Ab8011-001 |
GenDepot |
1mg |
EUR 334 |
EGFR antibody (Alexa Fluor 488) |
61R-E109BAF |
Fitzgerald |
125 ug |
EUR 706 |
Description: Mouse monoclonal EGFR antibody (Alexa Fluor 488) |
SAM FCM (Alexa Fluor 647) |
abx098902-100tests |
Abbexa |
100 tests |
EUR 1233 |
- Shipped within 5-10 working days.
|
SAM FCM (Alexa Fluor 488) |
abx098904-60tests |
Abbexa |
60 tests |
EUR 1358 |
- Shipped within 5-10 working days.
|
Anti-RPSA Alexa Fluor® 488 |
A4-829-C100 |
ExBio |
0.1 mg |
EUR 310 |
Anti-CD40 antibody (Alexa-fluor 488) |
STJ170000 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: CD40 (48 to 50 kDa) is a transmembrane glycoprotein mainly expressed on the surface of B cells and also expressed on monocytes, dendritic cells, and thymic epithelium. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the low affinity nerve growth factor (NGF) receptor and CD95/Fas. CD40 is the receptor for CD40 ligand. CD40L (CD40L, CD154, gp39, and TRAM) belongs to the TNF gene family and is expressed more widely than CD40, predominantly on activated CD4+ T cells. Following interaction with CD40 ligand, CD40 mediates a number of major immunoregulatory functions, central to the control of thymus dependent humoral immunity and may be critical in the development of cell mediated immune responses. Other biological actions include B cell homotypic adhesion, proliferation, immunoglobulin isotype switch, and secretion. Activation of CD40 has also been shown to inhibit the growth of certain B cell lymphomas and to induce the death of transformed cells of mesenchymal or epithelial origin |
Anti-LAMP3 antibody (Alexa-fluor 488) |
STJ170004 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
Anti-LAMP3 antibody (Alexa-fluor 546) |
STJ170005 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
Anti-LAMP3 antibody (Alexa-fluor 647) |
STJ170006 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
Anti-IL3RA antibody (Alexa-fluor 488) |
STJ170009 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
Anti-IL3RA antibody (Alexa-fluor 546) |
STJ170010 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
Anti-IL3RA antibody (Alexa-fluor 647) |
STJ170011 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
Anti-CD207 antibody (Alexa-fluor 488) |
STJ170014 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
Anti-CD207 antibody (Alexa-fluor 546) |
STJ170015 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
Anti-CD207 antibody (Alexa-fluor 647) |
STJ170016 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
Anti-IL7R antibody (Alexa-fluor 488) |
STJ170020 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
Anti-IL7R antibody (Alexa-fluor 546) |
STJ170021 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
Anti-IL7R antibody (Alexa-fluor 647) |
STJ170022 |
St John's Laboratory |
100 µg |
EUR 393 |
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
Goat anti Mouse IgG1 (Alexa Fluor 488) |
43R-1649 |
Fitzgerald |
500 ug |
EUR 570 |
Description: Goat anti Mouse IgG1 secondary antibody (Alexa Fluor 488) |
Anti-Hu CD16 Alexa Fluor® 488 |
A4-646-T100 |
ExBio |
100 tests |
EUR 269 |
Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
50337 |
Alpha Diagnostics |
0.5 ml |
EUR 225 |
Alpha Fluor™ 594 C5 Maleimide |
1891 |
AAT Bioquest |
1 mg |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Streptavidin-Alexa594 (Alexas fluor 594) conjugate |
SV-A594-100 |
Alpha Diagnostics |
100 tests |
EUR 225 |
Alpha Fluor™ 532 acid [equivalent to Alexa Fluor™ 532 acid] |
1795 |
AAT Bioquest |
10 mg |
EUR 393 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
AF350 Phalloidin [equivalent to Alexa Fluor® 350 phalloidin] |
23150 |
AAT Bioquest |
300 Tests |
EUR 306 |
- R-phrase: R23, R24, R25
- H-Phrase: H301, H311, H331
- Symbol for dangerous compounds: T
- UNSPEC Code: 12352200
|
AF488 Phalloidin [equivalent to Alexa Fluor® 488 phalloidin] |
23153 |
AAT Bioquest |
300 Tests |
EUR 306 |
- R-phrase: R23, R24, R25
- H-Phrase: H301, H311, H331
- Symbol for dangerous compounds: T
- UNSPEC Code: 12352200
|
AF350-streptavidin conjugate [Streptavidin, Alexa Fluor™ 350 Conjugate] |
16890 |
AAT Bioquest |
1 mg |
EUR 176 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
AF488-streptavidin conjugate [Streptavidin, Alexa Fluor™ 488 Conjugate] |
16891 |
AAT Bioquest |
1 mg |
EUR 176 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Donkey anti Goat IgG (H + L) (Alexa Fluor 647) |
43R-ID028AF |
Fitzgerald |
500 ug |
EUR 430 |
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 647) |
Donkey anti Chicken IgY (H + L) (Alexa Fluor 647) |
43R-ID060AF |
Fitzgerald |
300 ug |
EUR 425 |
Description: Donkey anti Chicken IgY (H + L) (Fab'2) (Alexa Fluor 647) |
Anti-Hu CD72 Alexa Fluor® 488 |
A4-310-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Bov CD9 Alexa Fluor® 488 |
A4-354-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD30 Alexa Fluor® 700 |
A7-455-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD94 Alexa Fluor® 700 |
A7-727-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD56 Alexa Fluor® 700 |
A7-789-T100 |
ExBio |
100 tests |
EUR 269 |
Goat Anti-Rabbit IgG(H+L) Alexa Fluor 647–conjugated |
S0013 |
Affbiotech |
200ul |
EUR 304 |
Goat Anti-Mouse IgG(H+L) Alexa Fluor 647–conjugated |
S0014 |
Affbiotech |
200ul |
EUR 304 |
Goat Anti-Mouse IgG(H+L) Alexa Fluor 488–conjugated |
S0017 |
Affbiotech |
200ul |
EUR 304 |
Goat Anti-Rabbit IgG(H+L) Alexa Fluor 488–conjugated |
S0018 |
Affbiotech |
200ul |
EUR 304 |
Donkey Anti-Rabbit IgG (H+L), Alexa Fluor® 488 Conjugated |
Ab8032-001 |
GenDepot |
0.5mg |
EUR 435 |
Anti-Hu CD3 zeta (pY153) Alexa Fluor® 488 |
A4-686-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY72) Alexa Fluor® 488 |
A4-712-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY142) Alexa Fluor® 488 |
A4-730-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY111) Alexa Fluor® 488 |
A4-737-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY153) Alexa Fluor® 647 |
A6-686-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY72) Alexa Fluor® 647 |
A6-712-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY142) Alexa Fluor® 647 |
A6-730-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Hu CD3 zeta (pY111) Alexa Fluor® 647 |
A6-737-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-LAMP3 (human) Monoclonal Antibody (104G4) (Alexa Fluor® 488) |
M09406 |
BosterBio |
100ug |
EUR 565 |
Description: Mouse Monoclonal LAMP3 (human) Antibody (104G4) (Alexa Fluor® 488). Validated in IHC and tested in Human. |
Anti-Langerin (human) Monoclonal Antibody (DCGM4/122D5) (Alexa Fluor® 488) |
M02316 |
BosterBio |
100ug |
EUR 580 |
Description: Mouse Monoclonal Langerin (human) Antibody (DCGM4/122D5) (Alexa Fluor® 488). Validated in IHC and tested in Human. |
Rabbit Anti-Rat IgG (H+L)-Alexa 488 Fluor conjugate (adsorbed with human IgG) |
50336 |
Alpha Diagnostics |
0.5 ml |
EUR 225 |
Alpha Fluor™ 488 amine |
1705 |
AAT Bioquest |
1 mg |
EUR 306 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Alpha Fluor™ 488 Hydroxylamine |
1900 |
AAT Bioquest |
1 mg |
EUR 306 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Tide Fluor 2-LL-37 |
H-8286.0100 |
Bachem |
0.1mg |
EUR 312 |
Description: Sum Formula: C205H340N60O53+dye |
Tide Fluor 2-LL-37 |
H-8286.0500 |
Bachem |
0.5mg |
EUR 1017 |
Description: Sum Formula: C205H340N60O53+dye |
Anti-Cytokeratins Alexa Fluor488 |
A4-108-C025 |
ExBio |
0.025 mg |
EUR 175 |
Anti-Cytokeratins Alexa Fluor488 |
A4-108-C100 |
ExBio |
0.1 mg |
EUR 310 |
Anti-PSMA Alexa Fluor488 |
A4-539-C025 |
ExBio |
0.025 mg |
EUR 227 |
Anti-PSMA Alexa Fluor488 |
A4-539-C100 |
ExBio |
0.1 mg |
EUR 414 |
Anti-FoxP3 Alexa Fluor488 |
A4-601-C025 |
ExBio |
0.025 mg |
EUR 201 |
Anti-FoxP3 Alexa Fluor488 |
A4-601-C100 |
ExBio |
0.1 mg |
EUR 362 |
Anti-Phosphotyrosine Alexa Fluor647 |
A6-263-C025 |
ExBio |
0.025 mg |
EUR 154 |
Anti-Phosphotyrosine Alexa Fluor647 |
A6-263-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-LCK Alexa Fluor647 |
A6-269-C025 |
ExBio |
0.025 mg |
EUR 206 |
Anti-LCK Alexa Fluor647 |
A6-269-C100 |
ExBio |
0.1 mg |
EUR 373 |
Anti-FoxP3 Alexa Fluor647 |
A6-601-C025 |
ExBio |
0.025 mg |
EUR 201 |
Anti-FoxP3 Alexa Fluor647 |
A6-601-C100 |
ExBio |
0.1 mg |
EUR 362 |
Metal Fluor™ Zn-520, AM |
21263 |
AAT Bioquest |
1 mg |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
Alpha Fluor™ 488 NHS Ester |
1812 |
AAT Bioquest |
1 mg |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Alpha Fluor™ 532 NHS Ester |
1819 |
AAT Bioquest |
1 mg |
EUR 219 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Helix Fluor™ 6-JOE Phosphoramidite |
6046 |
AAT Bioquest |
100 umoles |
EUR 50 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12171501
|
Tide Fluor 2-LL-37 (scrambled) |
H-8288.0100 |
Bachem |
0.1mg |
EUR 312 |
Description: Sum Formula: C205H340N60O53+dye |
Tide Fluor 2-LL-37 (scrambled) |
H-8288.0500 |
Bachem |
0.5mg |
EUR 1017 |
Description: Sum Formula: C205H340N60O53+dye |
Tide Fluor 5WS-o-Conotoxin GVIA |
H-8356.0100 |
Bachem |
0.1mg |
EUR 1146 |
Description: Sum Formula: C120H182N38O43S6+dye |
Streptavidin-Alexa488 (Alexas fluor 488) conjugate |
SV-A488-100 |
Alpha Diagnostics |
100 tests |
EUR 225 |
Anti-Cytokeratin 18 Alexa Fluor488 |
A4-106-C025 |
ExBio |
0.025 mg |
EUR 186 |
Anti-Cytokeratin 18 Alexa Fluor488 |
A4-106-C100 |
ExBio |
0.1 mg |
EUR 331 |
Anti-Cytokeratin 19 Alexa Fluor488 |
A4-120-C025 |
ExBio |
0.025 mg |
EUR 186 |
Anti-Cytokeratin 19 Alexa Fluor488 |
A4-120-C100 |
ExBio |
0.1 mg |
EUR 331 |
Anti-Ki-67 Alexa Fluor488 |
A4-155-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Ki-67 Alexa Fluor488 |
A4-155-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD45 Alexa Fluor488 |
A4-160-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD193 Alexa Fluor488 |
A4-161-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD279 Alexa Fluor488 |
A4-176-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD43 Alexa Fluor488 |
A4-220-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD43 Alexa Fluor488 |
A4-220-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD44 Alexa Fluor488 |
A4-221-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD44 Alexa Fluor488 |
A4-221-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD45 Alexa Fluor488 |
A4-222-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD45 Alexa Fluor488 |
A4-222-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD55 Alexa Fluor488 |
A4-230-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD55 Alexa Fluor488 |
A4-230-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD50 Alexa Fluor488 |
A4-266-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD50 Alexa Fluor488 |
A4-266-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD31 Alexa Fluor488 |
A4-273-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD31 Alexa Fluor488 |
A4-273-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD147 Alexa Fluor488 |
A4-274-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD147 Alexa Fluor488 |
A4-274-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD34 Alexa Fluor488 |
A4-297-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD34 Alexa Fluor488 |
A4-297-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD105 Alexa Fluor488 |
A4-298-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD105 Alexa Fluor488 |
A4-298-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD41 Alexa Fluor488 |
A4-309-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD41 Alexa Fluor488 |
A4-309-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD72 Alexa Fluor488 |
A4-310-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD63 Alexa Fluor488 |
A4-343-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD63 Alexa Fluor488 |
A4-343-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD13 Alexa Fluor488 |
A4-396-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD13 Alexa Fluor488 |
A4-396-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-HLA-G Alexa Fluor488 |
A4-431-C025 |
ExBio |
0.025 mg |
EUR 217 |
Anti-HLA-G Alexa Fluor488 |
A4-431-C100 |
ExBio |
0.1 mg |
EUR 394 |
Anti-HLA-G Alexa Fluor488 |
A4-437-C025 |
ExBio |
0.025 mg |
EUR 217 |
Anti-HLA-G Alexa Fluor488 |
A4-437-C100 |
ExBio |
0.1 mg |
EUR 394 |
Anti-Hu CD300a Alexa Fluor488 |
A4-501-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-HLA-A2 Alexa Fluor488 |
A4-556-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-HLA-A2 Alexa Fluor488 |
A4-556-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-CD3 zeta Alexa Fluor488 |
A4-568-C100 |
ExBio |
0.1 mg |
EUR 269 |
Anti-Ms CD8a Alexa Fluor488 |
A4-579-C025 |
ExBio |
0.025 mg |
EUR 139 |
Anti-Ms CD8a Alexa Fluor488 |
A4-579-C100 |
ExBio |
0.1 mg |
EUR 238 |
Anti-Hu CD326 Alexa Fluor488 |
A4-582-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD3 Alexa Fluor488 |
A4-631-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD16 Alexa Fluor488 |
A4-646-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD150 Alexa Fluor488 |
A4-660-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD107a Alexa Fluor488 |
A4-671-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD107a Alexa Fluor488 |
A4-671-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD107b Alexa Fluor488 |
A4-672-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD107b Alexa Fluor488 |
A4-672-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD73 Alexa Fluor488 |
A4-675-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD11b Alexa Fluor488 |
A4-681-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD11b Alexa Fluor488 |
A4-681-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD35 Alexa Fluor488 |
A4-703-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD305 Alexa Fluor488 |
A4-713-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD161 Alexa Fluor488 |
A4-729-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD144 Alexa Fluor488 |
A4-770-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-HLA-ABCE Alexa Fluor488 |
A4-813-C100 |
ExBio |
0.1 mg |
EUR 373 |
Anti-Ki-67 Alexa Fluor647 |
A6-155-T025 |
ExBio |
25 tests |
EUR 154 |
The relationship between BMI and pain varies by MSD, with a stronger relationship in the osteoarthritis group and a less clear relationship in the back and lower back pain group. There is a high prevalence of overweight / obesity among veterans with MSD. The high level of BMI (> 27 kg / m2) is associated with an increase in pain opportunities, the most obvious among veterans with osteoarthritis.